Celon Pharma SA Net Asset Quality Index
Celon Pharma SA net asset quality index. Celon Pharma SA (CLN) has a Net Asset Quality Index of 78.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of zł670.73 Million minus total liabilities of zł141.95 Million yields net assets of zł528.78 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Celon Pharma SA cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Celon Pharma SA (2012–2025)
Net asset quality index of Celon Pharma SA from 2012 to 2025. This chart shows how Celon Pharma SA's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 78.8%, representing net assets of zł528.78 Million against total assets of zł670.73 Million PLN. See Celon Pharma SA (CLN) shareholders funds for net asset value and shareholders' equity analysis.
Celon Pharma SA Net Asset Quality Index by Year (2012–2025)
Celon Pharma SA net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Celon Pharma SA from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Celon Pharma SA (CLN) total market value.
| Year | Quality Index | Net Assets (PLN) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.7% | zł382.99 Million | zł457.46 Million | zł74.47 Million | ▲ +1.9 pp |
| 2024 | 81.9% | zł445.21 Million | zł543.79 Million | zł98.59 Million | ▲ +3.6 pp |
| 2023 | 78.3% | zł445.56 Million | zł569.31 Million | zł123.75 Million | ▼ -0.5 pp |
| 2022 | 78.8% | zł479.65 Million | zł608.93 Million | zł129.29 Million | ▲ +0.4 pp |
| 2021 | 78.3% | zł554.00 Million | zł707.14 Million | zł153.14 Million | ▲ +16.6 pp |
| 2020 | 61.8% | zł434.67 Million | zł703.64 Million | zł268.97 Million | ▼ -13.5 pp |
| 2019 | 75.3% | zł445.04 Million | zł591.35 Million | zł146.31 Million | ▼ -4.3 pp |
| 2018 | 79.6% | zł448.73 Million | zł563.67 Million | zł114.94 Million | ▼ -4.2 pp |
| 2017 | 83.8% | zł439.85 Million | zł525.05 Million | zł85.20 Million | ▼ -2.9 pp |
| 2016 | 86.7% | zł402.50 Million | zł464.32 Million | zł61.82 Million | ▲ +26.8 pp |
| 2015 | 59.9% | zł100.82 Million | zł168.29 Million | zł67.47 Million | ▼ -6.1 pp |
| 2014 | 66.0% | zł69.62 Million | zł105.44 Million | zł35.82 Million | ▲ +2.8 pp |
| 2013 | 63.2% | zł52.20 Million | zł82.59 Million | zł30.39 Million | ▼ -16.4 pp |
| 2012 | 79.6% | zł55.57 Million | zł69.80 Million | zł14.22 Million | — |